179 related articles for article (PubMed ID: 26908738)
1. Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine.
Chesson HW; Laprise JF; Brisson M; Markowitz LE
J Infect Dis; 2016 Jun; 213(11):1694-700. PubMed ID: 26908738
[TBL] [Abstract][Full Text] [Related]
2. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
Chesson HW; Markowitz LE; Hariri S; Ekwueme DU; Saraiya M
Hum Vaccin Immunother; 2016 Jun; 12(6):1363-72. PubMed ID: 26890978
[TBL] [Abstract][Full Text] [Related]
3. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: A comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection.
Choi W; Shim E
Prev Med; 2024 Jan; 178():107743. PubMed ID: 37866695
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States.
Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
Vaccine; 2018 Jul; 36(29):4362-4368. PubMed ID: 29887325
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia.
Wondimu A; Postma MJ; van Hulst M
Vaccine; 2022 Mar; 40(14):2161-2167. PubMed ID: 35248423
[TBL] [Abstract][Full Text] [Related]
7. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
Zhang Z; Zhang J; Xia N; Zhao Q
Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
[TBL] [Abstract][Full Text] [Related]
8. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
[TBL] [Abstract][Full Text] [Related]
9. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
Petrosky E; Bocchini JA; Hariri S; Chesson H; Curtis CR; Saraiya M; Unger ER; Markowitz LE;
MMWR Morb Mortal Wkly Rep; 2015 Mar; 64(11):300-4. PubMed ID: 25811679
[TBL] [Abstract][Full Text] [Related]
10. Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom.
Owusu-Edusei K; Palmer C; Ovcinnikova O; Favato G; Daniels V
J Health Econ Outcomes Res; 2022; 9(1):140-150. PubMed ID: 35795155
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model.
Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
Vaccine; 2020 Nov; 38(50):8032-8039. PubMed ID: 33121846
[TBL] [Abstract][Full Text] [Related]
12. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
15. The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong.
Cheung TH; Cheng SSY; Hsu DC; Wong QW; Pavelyev A; Walia A; Saxena K; Prabhu VS
Cost Eff Resour Alloc; 2021 Nov; 19(1):75. PubMed ID: 34801050
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
17. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.
Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
Hum Vaccin Immunother; 2019; 15(2):503-507. PubMed ID: 30252583
[TBL] [Abstract][Full Text] [Related]
18. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
19. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.
Laprise JF; Drolet M; Boily MC; Jit M; Sauvageau C; Franco EL; Lemieux-Mellouki P; Malagón T; Brisson M
Vaccine; 2014 Oct; 32(44):5845-53. PubMed ID: 25131743
[TBL] [Abstract][Full Text] [Related]
20. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]